MedWatch

Copies affect Leo Pharma’s US operations

According to Leo Pharma, it could cost the Danish pharmaceutical company up to half a billion DKK over the next six months that generic copies of the psoriasis ointment Dovonex has hit the US market. The company is currently working on a solution to minimize the loss.

Foto: LEO Pharma/PR

Leo Pharma should be prepared to accept a substantial dip in earnings from the company’s psoriasis ointment Dovonex. After the generics company Sandoz, owned by Swiss company Novartis, launched a copy of the ointment on the US market in August, the Danish pharmaceutical company stands to lose up to half a billion DKK in turnover, according to Danish business daily Børsen.

IMS Health reports that Dovonex sold for 118.8 million dollars (DKK 710.4) in the 12-month-period ending May 2012. It is normal for generics manufacturers to conquer about 80 % of a market, when a drug goes of patent in the US.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Dansk Biotek skifter navn

Den danske brancheorganisation for biotekselskaber, Dansk Biotek, skifter navn til "Danish Bio - Dansk Biotek" for at imødekomme den stigende internationalisering af branchen, fortæller formand.

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier